EirGenix Reports the Completion of the P-I Clinical Trial for EG1206A (biosimilar, pertuzumab) to Treat HER2-Positive Breast Cancer
Shots:
- The company has completed the P-I trial (EGC101) in the EU evaluating the second breast cancer biosimilar EG1206A vs Perjeta in patients with HER2+ breast cancer. The clinical data analysis showed that the main test indicators have met the PK bioequivalence standard
- EG1206A, a biosimilar drug of Perjeta has a unique binding mechanism for HER2 receptors producing a dual blockade effect. The P-III trial of EG1206A is expected to be initiated shortly, estimated that the evaluation of the primary EPs will be completed within 2yrs.
- To further expedite the introduction of the biosimilar globally, EirGenix has been in talks with global pharmaceutical companies about licensing the marketing rights to EG1206A
Ref: PR Newswire | Image: EirGenix
Related News:- EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
